Pulse Biosciences (NASDAQ:PLSE) Releases Quarterly Earnings Results

Pulse Biosciences (NASDAQ:PLSE) issued its quarterly earnings results on Wednesday. The company reported ($0.21) EPS for the quarter, RTT News reports. During the same period last year, the firm posted ($0.19) EPS.

Pulse Biosciences Trading Down 10.2 %

NASDAQ:PLSE traded down $1.80 during mid-day trading on Thursday, hitting $15.92. The company had a trading volume of 52,394 shares, compared to its average volume of 199,585. The business has a fifty day simple moving average of $17.70 and a 200-day simple moving average of $14.22. The firm has a market capitalization of $975.74 million, a price-to-earnings ratio of -20.01 and a beta of 1.74. Pulse Biosciences has a 1 year low of $4.24 and a 1 year high of $22.69.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded Pulse Biosciences to a “sell” rating in a research note on Friday, September 20th.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.